Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has granted stock options to four new employees as employment inducements. The options total 238,500 shares with an exercise price of $3.69 per share, matching the closing price on July 31, 2025.

The options will vest over a 4-year period, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter. These 10-year term options were granted under Nasdaq Listing Rule 5635(c)(4) and are subject to continued employment with Akebia.

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of Akebia’s common stock on July 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $3.69 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco
mcarrasco@akebia.com

FAQ

What stock options did Akebia Therapeutics (AKBA) grant to new employees in July 2025?

Akebia granted options to purchase 238,500 shares to four new employees at an exercise price of $3.69 per share, with a 4-year vesting schedule.

What is the vesting schedule for Akebia's (AKBA) July 2025 employee stock options?

The options vest over 4 years, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, subject to continued employment.

What is the exercise price for Akebia's (AKBA) July 2025 inducement grants?

The exercise price is $3.69 per share, which was equal to Akebia's closing stock price on July 31, 2025.

Under which rule were Akebia's (AKBA) July 2025 stock options granted?

The options were granted under Nasdaq Listing Rule 5635(c)(4) as inducement material for new employees entering employment with Akebia.